Current State Of Longevity Clinical Trials – Anti Aging News

Aging can be seen as one of the biggest risk factors for developing many diseases such as cancer, osteoporosis, cardiovascular disease, and Alzheimers disease. Therapies targeting aging may help to reduce suffering and benefit humanity.

Longevity drug development has evolved into an industry priority, as such a number of companies are working on developing therapies that target aging some of which are currently involved in clinical trials.

Currently there arent any longevity drugs to have received regulatory approval, although a number of therapies have passed phase I and phase II clinical human trials, there are even a few phase III trials with all of the developers racing to be the first to go to market.

Many companies working in the space of longevity drug development are more advanced than traditional biomedical companies. They are considered to be next generation because this space of research and development integrates numerous scientific and technical subdomains such as geroscience, artificial intelligence, and digital medicine. Advanced methods of diagnostics and prognostic assessments, and next generation techniques for conducting clinical trials are used by these companies compared to conventional standards which are largely based on in vitro experiments and model organisms.

Developing drugs for longevity may well be one of the more complex areas in drug discovery, as longevity focuses on prevention rather than treatment which requires complete optimization of health at the deepest levels to target biological systems that control disease.

There are 9 hallmarks of aging which are considered to be at the root causes of aging in the longevity industry, discoveries in these categories has led to clinical trials, and each trial is a step closer to ameliorating these hallmarks.

The 9 categories of longevity drugs include: genomic instability; telomere attrition; epigenetic alterations; loss of proteostasis; cellular senescence; mitochondrial dysfunction; deregulated nutrient sensing; altered intercellular communication, and stem cell exhaustion.

Longevity drugs that are currently in preclinical development include: GDF11 by Elevian; SENSOlytics by Oisin Biotechnologies; Ectopic replacement organs by Lygenesis; Egg quality restoration drugs by Jumpstart Fertility; MitoSens by SENS Research Foundation; Telomerase gene therapy, Preclinical in vivo by CNIO; Telomerase therapy and proprietary iTR technology by AgeX Therapeutics; OSKM- OCT4, Sox2, Klf, and c-Myc by Salk; OSKMLN- Oct4, Sox2, Klf4, and c-Myc LIN28, and Nanog by Turn.Bio; Lysoclear by Ichor Therapeutics; Cardizyme and Alzyme by Covalent Bioscience; Klotho by UCSF; FOXO4-DRI by Cleara Biotech; Small molecule senolytics by Antixerene; and machine learning platforms to identify peptides by Spotlight Biosciences.

Longevity drugs that have completed preclinical development include: NMD at Sinclair Lab; Gene therapy for restoration of short telomeres at Telocyte; UBX1967 at Unity Biotechnology; and Next Gen Apheresis at Conboy Lab.

Longevity drugs currently in clinical trials include: Fisetin at Mayo Clinic; Mesenchymal stem cell therapy at CRATUS; RTB101 at resTORbio; SRK-015 at Scholar Rock; SM04690 at Samumed; UBX1967 at Unity Biotechnology; J147 at Salk; NPT088 at The Michael J. Fox Foundation; Metformin at AFAR and the Albert Einstein College of Medicine; and Quercetin and Dasatinib at The Scripps Research Institute.

Longevity drugs currently in phase III clinical trials include: SM04690 at Samumed; and Targeting Aging with Metformin at the American Federation for Aging Research and the Albert Einstein College of Medicine.

Longevity drugs currently in phase II clinical trials include: UBX0101 at Unity Biotech; Quercetin and Dastinib at the Scripps Research Institute; Fisetin at the Mayo Clinic; RTB101 at resTORbio; and MSCs therapy at Cratus.

Longevity drugs currently in phase I clinical trials include: J147 at Salk; SRK-015 at Scolar Rock; and NPT088 at the Michael J. Fox Foundation and Proclara Bioscience.

Excerpt from:
Current State Of Longevity Clinical Trials - Anti Aging News

Crigler-Najjar Syndrome Market Insights 2019-2026: Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp – US Trade Media

Crigler-Najjar Syndrome market research report has been formulated by using basic steps to conduct market research analysis which includes survey, focus groups, personal interviews, observations and field trials. This Crigler-Najjar Syndrome market report cover strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The report provides an all-inclusive study on production capacity, consumption, import and export for all major regions across the globe. With the use of excellent resources and latest tools, this best in class Crigler-Najjar Syndrome market research report has been created to aid your business growth.

CriglerNajjar syndromeis rare genetic liver disorder characterized by abnormal accumulation of bilirubin, a yellow pigment produced by the liver. This accumulation is caused by deficiency of the enzyme called UGT1A1. This enzyme is responsible for the conversion of bilirubin into a substance that can be eliminated. CriglerNajjar Syndrome can cause significant neurological damage.

According to the statistics published in the U.S. Department of Health & Human Services, an estimated annual prevalence of Crigler-Najjar syndrome is 1 in one million newborns worldwide. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth

Few of the major competitors currently working in the global CriglerNajjar syndrome market are International Stem Cell Corporation, Promethera, Selecta Biosciences, Inc, LOGICBIO THERAPEUTICS, INC, Genethon, Audentes Therapeutics, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett and others

Request for Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-criglernajjar-syndrome-market

Global CriglerNajjar Syndrome Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market.

Market Drivers

Segmentation:Global CriglerNajjar Syndrome Market

By Treatment

By Drugs

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Key Developments in the Market:

Browse Full Report with Details TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-criglernajjar-syndrome-market

Competitive Analysis:

Global CriglerNajjar syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global CriglerNajjar syndrome market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

There are 15 Chapters to display the Global Crigler-Najjar Syndrome Drug market

Chapter 1, Definition, Specifications and Classification of Crigler-Najjar Syndrome Drug , Applications of Crigler-Najjar Syndrome Drug , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Crigler-Najjar Syndrome Drug , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Crigler-Najjar Syndrome Drug Segment Market Analysis (by Type);Chapter 7 and 8, The Crigler-Najjar Syndrome Drug Segment Market Analysis (by Application) Major Manufacturers Analysis of Crigler-Najjar Syndrome Drug ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type ALXN-1540, AT-342, HepaStem, Others, Market Trend by Application Hospital, Clinic, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Crigler-Najjar Syndrome Drug ;Chapter 12, Crigler-Najjar Syndrome Drug Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Crigler-Najjar Syndrome Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Inquiry before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-criglernajjar-syndrome-market

Research Methodology:Global CriglerNajjar Syndrome Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaserequest an analyst callor can drop down your enquiry.

The key research methodology used byDBMR researchteam is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons for Buying Crigler-Najjar Syndrome Drug market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:Sopan.gedam@databridgemarketresearch.com

Original post:
Crigler-Najjar Syndrome Market Insights 2019-2026: Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp - US Trade Media

Global Stem Cell Antibody Market Analysis, Growth, Size, Share, Demand & Forecast 2019-2026: Thermo Fisher Scientific, Inc., Merck Group, Abcam…

Global Stem Cell Antibody Market research report has all the necessary vital details asked by the clients or any audiences in terms of market advantages or disadvantages and future market scope all mentioned in a very crystal clear manner. The report eloquently mentioned all the information regarding market competitors, growth rate, revenue ups and downs, regional players, industrial players, and applications. Even the most measly information depicting market figures are comprehensively analyzed and before being presented to the clients. The industrial players Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.) are all provided so as to make it easier for the audiences to understand the market growth rate. The current Stem Cell Antibody market research report has demonstrated all the vital market growth factors and economic fluctuations mentioned owing to the immense attention gained in recent years.

Click Here To Access The Sample Report:: http://www.reportsbuzz.com/request-for-sample.html?repid=62304

Global Market portal aims to provide reports like these in order to draw the attention of many of the clients wanting to extrapolate some of the vital details of the Stem Cell Antibody market on a global scale. The Stem Cell Antibody market dossier talks about the market segmentation created on the basis of consensus made, product type, governments norms, key industrial players, competitive landscapes, applications, end-user, topological players, and more. The report presents a demand for individual segment in each region. It demonstrates various segments Primary Antibodies, Secondary Antibodies and sub-segments Proteomics, Drug Development, Genomics of the global Stem Cell Antibody market. The current report data simulates the market status and investment gains or losses in a very illustrative manner so as to provide the analyzed data in a very refreshed format.

Read Detailed Index Of Full Research Study @:: http://www.reportsbuzz.com/62304/global-stem-cell-antibody-market-outlook-2018-2025/

Though the paper may have certain limitations in terms of providing the information, the record has purported all the deep-seated intricate information. The clients and other readers can have all the global Stem Cell Antibody market highlights provided in this very report. The geographical regions also play an important role in enhancing the growth and development of the global Stem Cell Antibody market. The report has all the vital information regarding supply and demand, market development enhancers, market share, sales distributors, and more advocated in a very formal pattern.

There are 15 Chapters to display the Global Stem Cell Antibody market

Chapter 1, Definition, Specifications and Classification of Stem Cell Antibody , Applications of Stem Cell Antibody , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Stem Cell Antibody , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Stem Cell Antibody Segment Market Analysis (by Type);Chapter 7 and 8, The Stem Cell Antibody Segment Market Analysis (by Application) Major Manufacturers Analysis of Stem Cell Antibody ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Primary Antibodies, Secondary Antibodies, Market Trend by Application Proteomics, Drug Development, Genomics;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Stem Cell Antibody ;Chapter 12, Stem Cell Antibody Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Stem Cell Antibody sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.reportsbuzz.com/inquiry-for-buying.html?repid=62304

See the article here:
Global Stem Cell Antibody Market Analysis, Growth, Size, Share, Demand & Forecast 2019-2026: Thermo Fisher Scientific, Inc., Merck Group, Abcam...

Reported stem cell treatment could give hope to Michael Schumacher – Stuff.co.nz

The news that Formula One legend Michael Schumacher was moved to a hospital in Paris last week for pioneering stem cell therapy has provoked a fever of hope and speculation among fans that his condition could be improved.

After suffering devastating head injuries in a ski accident almost six years ago, Schumacher was placed in a coma for six months and has been receiving treatment at his home in Switzerland. He has not been seen in public since the accident.

His privacy is closely guarded and, while it is understood he cannot walk or stand, and, according to former Ferrari manager, Jean Todt, he may still have trouble communicating, nothing has been confirmed officially.

No wonder then that fans have been so excited to hear Schumacher is now under the care of world-renowned cardiac surgeon Philippe Menasch, described as a "pioneer in cell surgery" at the Georges-Pompidou hospital in Paris.

READ MORE:* Schumacher 'conscious' after treatment*Corinna Schumacher provides rare update*Schumacher 'struggles' to communicate*Mick Schumacher trying to emulate his dad

Stem cells are cells that can differentiate or change into other types of cell, opening the possibility of replacing damaged cells with healthy ones. Scientists have been looking into their use since the Sixties, most successfully so far in cases of cancers of the blood or bone marrow. More than 26,000 patients are treated with blood stem cells in Europe each year.

And since the Eighties, skin stem cells have been used to grow skin grafts for patients with life-threatening burns; most recently, a new stem cell-based treatment to repair damage to the cornea (the surface of the eye) after an injury like a chemical burn, has received conditional approval in Europe.

But their flexibility offers hope for lots of illnesses and conditions including heart disease, MS and macular degeneration and clinical trials are progressing in all these areas. Chronic spinal cord injury is being researched with some promise, thanks to the Christopher & Dana Reeve Foundation, set up after actor Christopher Reeve was paralysed in a riding accident.

Crucially, for cases such as Schumacher, stem cells are also being explored for neurodegenerative diseases like Parkinson's and Alzheimer's and traumatic brain injuries like the one he suffered in a skiing accident in December 2013.

Head injuries are difficult to treat as brain damage cannot be undone and each case is different. Asked for comment by The Daily Telegraph, the hospital responded that they could neither confirm nor deny the presence of Schumacher.

However, if he is under the care of Menasch, it is likely he will have had stem cells delivered by an IV to the area of the body where it is felt they could work best - whether that is his head or heart.

CHRISTOPHE ENA/AP

Paris' Georges-Pompidou Hospital, where Michael Schumacher is reportedly a patient.

In a recent interview online, Menasch explained that stem cell treatment for cardiac conditions - his particular area of expertise - is in its infancy. "Nobody really knows how stem cells are working," he said. "They do not permanently transplant into the myocardium [the muscular tissue of the heart] - after a couple of days or weeks, they just disappear.

"But you still may have a functional benefit as during their transient stay in the heart," he explains in the Future Tech podcast, "as the cells release molecules into the tissue. The hypothesis is that the repair comes from the heart itself, stimulated by these molecules."

Should the stem cells have been intended for Schumacher's brain injury, research suggests that the treatment has potential. A University of Plymouth study published in the journal Cell Reports in June found that neural stem cells could be used to "wake up" and produce new neurons (nerve cells) and surrounding glial cells in the brain.

The research is in its infancy, says lead author Dr Claudia Barros, from the Institute of Translational and Stratified Medicine at the University of Plymouth, who acknowledges there is still a long way to go until such findings can be translated into human treatments.

"We are working to expand our findings, to bring us closer to the day when human neural stem cells can be controlled and efficiently used to facilitate brain damage repair, or even prevent brain cancer growth that is fuelled by stem-like cells," she says.

A Chinese study published last month in the journal Frontiers in Cellular Neuroscience examined the current state of progress into the effects of stem cell therapy on traumatic brain injury. But the researchers from Zhejiang University, Hangzhou warned much more work was needed: "Although a large number of basic studies have confirmed that stem cells have good effect in the craniocerebral injury," they said, "the safety of stem cells, the route of injection, the time of injection and the specific mechanism are all factors that affect the clinical application of stem cells, and are the important research point in the future study."

PREMA TEAM

Mick Schumacher doesn't mind the comparisons with his seven-time F1 champion father Michael.

In the UK, some applications of stem cell medicine are already available privately, although tightly controlled by the Human Tissue Authority and not in the brain.

Simon Checkley, CEO at the Regenerative Clinic in Brighton, explains: "It is possible to get stem cells from sources outside your body, like the umbilical cord or Wharton's jelly [the vitreous humour in the eyeball], but in the UK we can only take stem cells from our own bodies.

"It is possible to get them donated, but it is safer to use your own."

In some countries, stem cells can then be manipulated in a laboratory but that is illegal in the UK, says Checkley. "There is a concern with cultured stem cells which have been bred in a Petri dish that they may keep proliferating after you transplant them into a body. That, having triggered their growth, you can't stop it and no one knows what might happen."

At the Regenerative Clinic, stem cells are taken from adipose fat, where they are plentiful, and then injected back into the area to be treated - mostly arthritic joints.

"We are seeing fantastic results," Checkley says, "with reduced pain and improved mobility for 80 per cent of patients." He is considering a clinical trial which could see the treatment pass through the National Institute for Health and Care Excellence (NICE) and become available on the NHS.

The therapy is still only four years old, he emphasises. "We have treated 1000 patients so far and around the world, it's about 40,000. We need longer-term studies."

LUCA BRUNO/AP

Michael Schumacher has not been seen in public since suffering a serious brain injury in a skiing accident nearly six years ago.

This type of stem cell treatment is also offered in the UK for post-menopause vaginal atrophy and stress incontinence, Checkley says, plus the genital skin condition lichen sclerosis. In all these cases, he says, the mechanism is the same: the stem cells are not replicating dead or dying cells but acting as signalling devices, alerting the body that this is an area where healing is needed.

For stem cells to work in more complex conditions, they would need to be manipulated, Checkley says. In cases of brain injury or disease, that would mean altering stem cells so that they could be targeted more precisely. But he believes the role would be similar: "The idea is they would go to the area of greatest damage and signal the body to regrow tissue there."

Cost would be a huge factor, he points out. A treatment for arthritis costs about 6000 (NZ$11,700) at the Regenerative Clinic but an IV-led treatment for brain injury with manipulated stem cells could cost up to 50,000 (NZ$98,000). But then what price recovery from a traumatic brain injury? Full recovery thanks to stem cells would be a prize beyond value.

Go here to read the rest:
Reported stem cell treatment could give hope to Michael Schumacher - Stuff.co.nz

USC researchers untangle cellular reprogramming to help treat diseases – USC News

USC scientists have surmounted a big roadblock in regenerative medicine that has so far constrained the ability to use repurposed cells to treat diseases.

The researchers figured out how to reprogram cells to switch their identity much more reliably than present capabilities allow. The technique uses enzymes to untangle reprogramming DNA, somewhat similar to how a coiffeur conditions tangled hair. The technique works with near-perfect efficiency in mice and humans for all types of cells tested in the laboratories of USCs stem cell center.

Justin Ichidas lab is doing groundbreaking work in the field of stem cell research. (Photo/Damon Casarez)

The findings are significant because they clear an obstacle to help scientists find treatments for a wide range of diseases, especially neurologic impairments and conditions such as hearing loss.

This is a strategy for greatly improving our ability to perform cellular reprogramming, which could enable the regeneration of lost tissues and the study of diseases that cannot be biopsied from living patients today, said Justin Ichida, assistant professor in the department of stem cell biology and regenerative medicine at the Keck School of Medicine of USC.

The findings appear Thursday in Cell Stem Cell in a research paper titled, Mitigating antagonism between transcription and proliferation allows near-deterministic cellular reprogramming. Ichida is the lead author, joined by a team of researchers at the Keck School of Medicine.

Cellular reprogramming has enormous potential as a disease cure because it enables scientists to study cells and molecular processes at each step of disease progression in controlled conditions that have, until now, been impossible.

Reprogramming involves changing one cell into another type of cell, such as a blood cell into a muscle or nerve cell. Thats important for medical research because the technique can be used to recreate tissues lost to disease and to study diseases in tissues that cannot be biopsied from living patients.

The technique has been known for decades but hasnt met its potential. According to the USC team, thats because DNA does not respond well when manipulated to change itself. DNA molecules are twisty by nature, due to the double helix configuration. Reprogramming DNA requires uncoiling, yet when scientists begin to unravel the molecules, they knot up tighter. As a result, nucleotides become much more difficult to work with and cells wont replicate properly, Ichida explained. Current untangling techniques only work 1% of the time.

Think of it as a phone cord, which is coiled to begin with, then gets more coils and knots when something is trying to harm it, Ichida said.

To smooth the kinks, the researchers treated cells with a chemical and genetic cocktail that activated enzymes called topoisomerases. The process works by using the enzymes to open the DNA molecules, release the coiled tension and lay it smoothly. In turn, that leads to more efficient cellular reprogramming, which increases the number of cells capable of simultaneous transcription and proliferation, which is needed to promote tissue growth. Its the equivalent of a DNA detangler that relaxes the tension of reprogramming transcription and makes it easier to replicate new cell colonies or tissues in a lab.

The technique has multiple advantages over existing current practice. For example, it worked nearly 100% of the time. It was proven in human and animal cells. It can be employed today in laboratories to study disease development and drug treatments. It has immediate utility for studying schizophrenia, Parkinsons, ALS and other neurological diseases; in those instances, new cells can be created to replace lost cells or acquire cells that cant be extracted from people.

Moreover, the technique does not involve stem cells; the reprogrammed cells are not brand new but the same age as the parent cell, which is advantageous for studying age-related disease. The reprogrammed cells may be better at creating age-accurate in vitro models of human disease, which are useful to study diverse degenerative diseases and accelerated aging syndromes.

The key is to understand development of disease at a cellular level and how disease affects organs, Ichida said. This is something you can do with stem cells, but in this case, it skips a stem cell state. Thats important because stem cells reset epigenetics and make new, young cells, but this method allows you to get adult cells of same age to better study diseases in aged individuals, which is important as the elderly suffer more diseases.

This latest advance in regenerative medicine complements other recent technological gains, including gene editing, tissue engineering and stem cell development. It represents a convergence in regenerative medicine moving scientists closer to treating many diseases. It has practical utility to accelerate targeted medical treatments and precision medicine.

A modern approach for disease studies and regenerative medicine is to induce cells to switch their identity, Ichida said. This is called reprogramming, and it enables the attainment of inaccessible tissue types from diseased patients for examination, as well as the potential restoration of lost tissue. However, reprogramming is extremely inefficient, limiting its utility. In this study, weve identified the roadblock that prevents cells from switching their identity. It turns out to be tangles on the DNA within cells that form during the reprogramming process. By activating enzymes that untangle the DNA, we enable near 100% reprogramming efficiency.

The study authors include Ichida and first authors Kimberley Babos and Kate Galloway (now an assistant professor at the Massachusetts Institute of Technology), as well as Kassandra Kisler, Madison Zitting, Yichen Li, Yingxiao Shi, Brooke Quintino, Robert Chow and Berislav Zlokovic of the Keck School of Medicine.

Funding for the study comes from a California Institute of Regenerative Medicine predoctoral training grant (TG2-01161); a Kirschstein-National Research Service Award postdoctoral fellowship (5F32NS092417-03); National Institutes of Health grants (R00NS077435, R01NS097850 and 5R01DC0155300); U.S. Department of Defense grant (W81XWH-15-1-0187); grants from the Donald E. and Delia B. Baxter Foundation, the Alzheimers Drug Discovery Foundation and the Association for Frontotemporal Degeneration, the Harrington Discovery Institute, the Tau Consortium, the Pape Adams Foundation, the Frick Foundation for ALS Research, the Muscular Dystrophy Association, the John Douglas French Alzheimers Foundation, the Merkin Family Foundation, the New York Stem Cell Foundation, the Keck School of Medicine of USC, the USC Broad Innovation Award and the Southern California Clinical and Translational Science.

Ichida is a co-founder and owner of AcuraStem, a California-based precision medicine company. USC also has a financial interest in AcuraStem. The other authors declare no competing interests.

More stories about: Faculty, Genetics, Research

Read more:
USC researchers untangle cellular reprogramming to help treat diseases - USC News

India- Cell Counting Market Size is Estimated to Value $10679.7 Million By 2025: Grand View Research, Inc – MENAFN.COM

(MENAFN - GetNews) According to report published by Grand View Research, The global cell counting market size was estimated at USD 5,477.9 million in 2016 and is anticipated to grow at a CAGR of 7.8% during the forecast period.

The global Cell Counting Market is expected to reach USD10,679.7 million by 2025, according to a new report by Grand View Research, Inc. Government initiatives working to promote development of cell therapeutics, wherein cell counting plays an imperative role, is expanding growth prospects for the market. As a result of extensive R & D activities, the number of diseases treated with the help of stem cells increased to 82 in 2016 from 27 in 2005. Also, California Institute for Regenerative Medicine's funding of USD 271 million for stem cell therapy created 12 R & D facilities in California, and these facilities brought approximately USD 543 million funding. In addition, it is also funded by National Institutes of Health (NIH), which approximately invested USD 1,429 million in 2015.

Increase in the number of collaborations of research institutes with various public and private entities to promote R & D has provided significant boost to the market. Growing number of proposed guidelines and recommendations for public and private laboratories to ensure high-quality standards and facilitate generation of accurate results are likely to improve adoption of instruments over the coming years. For instance, in May 2016, the International Society for Stem Cell Research updated guidelines for the development of cell-based therapy and research. The proposed guidelines focus on all stages of R & D and improve quality of preclinical studies.

Request a Sample Copy of the Global Cell Counting MarketResearch Report@https://www.grandviewresearch.com/industry-analysis/cell-counting-market/request/rs1

Further Key Findings From the Report Suggest:

Have Any Query? Ask Our Experts@https://www.grandviewresearch.com/inquiry/1619/ibb

Grand View Research has segmented the global cell counting market on the basis of product, end use, and region:

Cell Counting Product Outlook (Revenue, USD Million, 2014 - 2025)

Cell Counting End-use Outlook (Revenue, USD Million, 2014 - 2025)

Cell Counting Regional Outlook (Revenue, USD Million, 2014 - 2025)

Browse Related Reports @

Cell Lysis & Disruption Market:https://www.grandviewresearch.com/industry-analysis/cell-lysis-dissociation-market

Stem Cell Market: https://www.grandviewresearch.com/industry-analysis/stem-cells-market

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact Company Name: Grand View Research, Inc. Contact Person: Sherry James, Corporate Sales Specialist - U.S.A. Email: Send Email Phone: 1-415-349-0058, Toll Free: 1-888-202-9519 Address: 201, Spear Street, 1100 City: San Francisco State: California Country: United States Website: http://www.grandviewresearch.com/industry-analysis/cell-counting-market

MENAFN1809201900703268ID1099020745

Original post:
India- Cell Counting Market Size is Estimated to Value $10679.7 Million By 2025: Grand View Research, Inc - MENAFN.COM

CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO) – Yahoo Finance

Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific organization that promotes proteomics through international cooperation and collaborations, today recognized CyTOF inventors Dr. Scott Tanner, Dr. Vladimir Baranov, Dr. Olga Ornatsky and Dr. Dmitry Bandura and Fluidigm (FLDM) as winners of the 2019 Science and Technology Award. Announced at the 18th Annual HUPO World Congress in Adelaide, Australia, the award recognizes key innovators who have developed and commercialized industry-leading technologies, products or procedures to advance the understanding of the human proteome.

The award-winning mass spectrometry pioneers developed and commercialized cytometry by time-of-flight (CyTOF) at DVS, with the introduction of the first commercial CyTOF system in 2009. Designed to simplify highly multiplexed detection of cell surface and intracellular markers at single-cell resolution, CyTOF uses stable, isotopically distinct metal tags that can be easily distinguished in cells and tissues by atomic mass spectrometry.

In 2014, Fluidigm acquired DVS with a goal of expanding the use of CyTOF technology to new researchers and applications. Fluidigm introduced Helios, a CyTOF system, in 2015, and in 2017 it launched the Hyperion Imaging System for Imaging Mass Cytometry (IMC) applications. Fluidigm also now offers over 700 commercially available antibodies and pre-designed antibody panels for use with mass cytometry and IMC, including the recently introduced Maxpar Direct Immune Profiling System. Setting the new standard in human immune profiling, this profiling system provides the first complete sample-to-answer solution to quantify 37 different immune cell populations using a simple single-tube workflow with automated five-minute results reporting.

HUPO is excited to award Fluidigm with recognition of the developersScott, Vladimir, Olga and Dmitry with the 2019 HUPO Science and Technology award for the development of CyTOF technology, saidDr. RobertMoritz, HUPO Vice President and Chair of the HUPO Awards Committee.CyTOF is a transformative technology that is instrumental in driving groundbreaking discoveries in immunology, cancer, stem cell research, neurology and many more biological areas by enabling researchers to deeply profile protein biomarkers from cells and tissues at single-cell resolution.

Now used by leading cancer centers, academic medical centers and pharmaceutical organizations around the world, mass cytometry has powered significant advancements in the understanding of the immunome, with a growing list of more than 850 research publications.

We congratulate each member of the team for this notable award. Combining cytometry and inductively coupled plasma spectrometry to develop CyTOF technology was a landmark achievement, said Chris Linthwaite, President and CEO of Fluidigm. Over the past 10 years, we have developed an impressive suite of CyTOF systems and applications that enable researchers to understand the underlying mechanisms of disease, identify new biomarkers and accelerate therapeutic development. We are committed to further expanding the utility of this revolutionary technology to ultimately transform routine clinical testing of the immune system. With more than 50 clinical trials now powered by CyTOF, we see a tremendously bright future ahead.

About HUPOThe Human Proteome Organization (HUPO), is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training. HUPO is led currently by HUPO President and Professor Stephen Pennington of the University College Dublin in Ireland and HUPO Vice President and Professor Robert Moritz of the Institute for Systems Biology in Seattle, Washington.

About FluidigmFluidigm (FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Story continues

Fluidigm, the Fluidigm logo, CyTOF, Direct, Helios, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statement for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding anticipated benefits of newly introduced products and the growth and potential ofFluidigmproducts for mass cytometry and Imaging Mass Cytometry. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigms Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

HUPOChelsea PrangnellAssociation Manager604 558 5498office@hupo.org

FluidigmMedia: Michaeline BuntingSenior Director, Marketing 650 737 4190michaeline.bunting@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

The rest is here:
CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO) - Yahoo Finance

Genome-editing shows potential for treating HIV in patient – BioNews

16 September 2019

Chinese scientists have used the genome editing tool CRISPR in an attempt to treat HIV in a patient with blood cancer, for the first time.

The researchers created HIV-resistant stem cells, which they transplanted into the patient, where they survived for more than a year. Although the therapy did not reduce the level of HIV virus in the patient, no unintended genetic alterations were seen - one of the main areas of concern in genome editing.

'This is an important step towards using gene editing to treat human disease,' said Dr Fyodor Urnov, an expert on genome editing from University of California, Berkeley who was not involved in the study. 'Because of this study, we now know that these edited cells can survive in a patient, and they will stay there,' he told Nature News.

The team of scientists from Peking University Stem Cell Research Centre in Beijing, China, developed their approach to mimic the effects of a naturally occurring gene mutation that makes an individual resistant to HIV infection. The gene, CCR5, is responsible for making a protein that the HIV virus uses to get inside cells.

Three HIV patients are reportedly free of the virus after receiving stem cell transplants from donors with the protective mutation (see BioNews 990). However, as the mutation is rare, the team instead took stem cells from healthy donors and used genome-editing technology to delete the CCR5 gene. The edited stem cells were transplanted into the patient, as part of his cancer treatment.

The study is in marked contrast to the widely condemned work by Chinese scientist, Dr He Jiankui, who last year announced he had used genome-editing in human embryos to produce 'HIV-resistant' babies (see BioNews 977). One key difference of the current research is that the mutations were corrected in select adult cells, which would not alter the germline.

The edited cells persisted in the patient's blood during the 19-month study. However, only five to eight percent of the patient's total stem cells contained the protective edit, so the level of HIV was not significantly reduced, although the cancer was in remission.

Dr Rowena Johnston, director of research for amfAR, the Foundation for AIDS Research, told Wired: 'Ultimately, it comes down to the editing efficiency. That's the biggest challenge,' she said.

Professor Deng Hongkui who led the study told CNN that improving the efficiency of genome editing and optimising the transplantation procedure should accelerate the transition to clinical applications. 'The goal of a functional cure for AIDS is getting closer and closer,' he concluded.

The study was published in The New England Journal of Medicine.

See the rest here:
Genome-editing shows potential for treating HIV in patient - BioNews

New technology developed to screen for Huntington’s treatments – Drug Target Review

Researchers have created a new technology which enabled them to discover more about the causes of Huntingtons disease and which can be used to test drugs.

A study has used a new technology to understand more about the causations of Huntingtons disease, when the brain is in early developmental stages. According to the researchers, their findings can be used to study the disease and test potential drugs.

The research was conducted at Rockefeller University, US. The new method, in the lab of Professor Ali Brivanlou, uses neuroloids, tiny three-dimensional (3D) tissues cultures, to research cell groupings from human embryonic stem cells. The team was able to manipulate them in the lab to study how the disease arises.

Previous studies conducted by the researchers demonstrated that the condition arises in young neurons, but the new evidence indicates that the disease is caused during neurulation. This is when the brains cellular uniformity changes and distinct structures develop.

Developmental diseases can now be studied with new technology involving tiny brain models called neuruloids, shown here (credit: Laboratory of Stem Cell Biology and Molecular Embryology at The Rockefeller University).

When the researchers introduced into neuroloids a mutation known to cause Huntingtons, it consistently caused abnormally-shaped tissue structures.

The technology is now being used by the researchers to screen for drugs to prevent these abnormalities. They hope that their work will provide an alternative to similar work being done in animal models.

This technology really opens a door toward identifying that mechanisms that govern brain development, understanding how they go awry in disease and testing drugs that set these mechanisms back on the right course, says Brivanlou.

The findings were published in Nature Biotechnology.

Original post:
New technology developed to screen for Huntington's treatments - Drug Target Review

Device can produce synthetic human embryo-like parts – Washington Times

Scientists have developed a device that can produce dozens of synthetic human embryo-like parts simultaneously, calling it a tool that could improve the understanding of early human development.

By making such embryo-like structures from human stem cells, we have now available to us reliable experimental platforms to study human development without using human embryos, said Jianping Fu, one of the studys researchers and an associate professor of mechanical engineering at the University of Michigan.

Using devices that can manipulate fluids, the team of researchers were able to build embryo-like structures that resemble the core of an implanting human embryo, according to their article published last week in the journal Nature.

They created models of the amniotic ectoderm (which develops into the membrane that encloses a developing fetus) and the epiblast (which develops into all the cell types found in the human body) from human stem cells.

But the researchers excluded some important cell types from the embryo-like parts such as the trophoblast, which develops into the placenta, Mr. Fu said.

These embryo-like structures will be very powerful for advancing human embryology and reproductive biology. These embryo-like structures will also be useful for drug and toxicity screens to prevent pregnancy failure and birth defects, Mr. Fu said, adding that the team created them in controllable, reproducible and scalable ways.

The researchers made 12 to 15 embryo-like structures simultaneously at a 95% success rate, he said. Mr. Fu estimates that since 2016 the team has produced a few hundred embryo-like parts, keeping them less than four days.

The research has raised some ethical concerns about the idea of synthetic or artificial embryos, and Mr. Fu said he understands why some people might feel uncomfortable with the concept.

We are well aware of the sensitivity of our research, he said.

But he stressed that what he and the team have created are a mass of cells that mimic portions of a developing embryo that cannot develop into a fetus. He said the research team has no intention of creating a synthetic embryo and has no scientific reason to do so.

Josephine Johnston, director of research and research scholar at the Hastings Center, a bioethics research institute, said the teams study could raise the question of whether the embryo-like structures can be manipulated to create a fetus or whether these scientific techniques are bringing society closer to creating embryos from stem cells, which she described as likely implausible but understandable concerns for the public.

Ms. Johnston also questioned if the word embryo is the correct terminology for Mr. Fus teams work if the structures cannot develop in the womb, cautioning about language use to describe scientific models.

She said the stem cell work, along with cloning research and in vitro fertilization, raise similar concerns about the prospect of embryos having no family structure, and growing them inside peoples bodies and the manipulation of human life. Ms. Johnston added that religious concerns also play a role, which is why there is opposition to in vitro fertilization.

Anytime you are modeling human biology, you are only creating a model. So its never quite the same, and it cant necessarily answer all the same questions, she said of Mr. Fus teams study and the growth of cultured cells in a dish. But it is often a really important intermediary step before moving into doing experiments with humans.

The Fu teams work is the first demonstration of a bona fide human embryo-like structure and shows that such structures can be made from pluripotent or induced pluripotent stem cells in vitro, according to Anna-Katerina Hadjantonakis, a developmental biologist for the Sloan Kettering Institute.

Whats important is that this method is very robust and reproducible. Many identical structures can be generated at once, all having similar morphology which approximates to the human embryo, she said. The work opens the door and provides an accessible method for future studies in other laboratories.

Mr. Fu said he and the team are interested in continuing to polish the stem cell in vitro system using fluid-controlling devices to prolong the culture of human embryo-like structures.

He said other scientists have been able to create structures that resemble complete mouse embryos and implant those synthetic embryos into a surrogate. However, there has been no further development of artificial animal embryos beyond early implantation, he said.

Mr. Fu said he and his group created a 3D culture system using human stem cells two years ago. Other scientists have reported building 3D systems using mouse and human stem cells.

Sign up for Daily Newsletters

Follow this link:
Device can produce synthetic human embryo-like parts - Washington Times